AstraZeneca Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	60,439	58,739	54,073	45,811	44,351	37,417
Revenue	60,439	58,739	54,073	45,811	44,351	37,417
Revenue Growth (YoY)	9.93%	8.63%	18.04%	3.29%	18.53%	40.58%
Cost of Revenue	11,178	10,746	9,638	8,045	8,641	12,005
Gross Profit	49,261	47,993	44,435	37,766	35,710	25,412
Selling, General & Admin	20,472	20,072	19,453	18,036	17,460	14,673
Research & Development	14,163	13,851	12,243	10,306	9,669	8,049
Other Operating Expenses	-298	-222	-190	-275	-231	-207
Operating Expenses	34,337	33,701	31,506	28,067	26,898	22,515
Operating Income	14,924	14,292	12,929	9,699	8,812	2,897
Interest Expense	-1,409	-1,365	-1,403	-1,219	-917	-776
Interest & Investment Income	349	360	345	301	81	43
Earnings From Equity Investments	-12	-7	-28	-12	-5	-64
Currency Exchange Gain (Loss)	-31	-31	-42	-34	-16	-20
Other Non Operating Income (Expenses)	-247	-247	-134	-292	-370	-478
EBT Excluding Unusual Items	13,574	13,002	11,667	8,443	7,585	1,602
Merger & Restructuring Charges	-322	-262	-1,154	-581	-4,201	-1,283
Gain (Loss) on Sale of Investments	-	-	-	-	-	776
Gain (Loss) on Sale of Assets	154	154	60	292	216	509
Asset Writedown	-230	-230	-1,574	-434	-241	-2,069
Legal Settlements	-218	-218	-48	-1,013	-789	-48
Other Unusual Items	-44	-44	-260	192	-69	248
Pretax Income	12,914	12,402	8,691	6,899	2,501	-265
Income Tax Expense	2,521	2,169	1,650	938	-792	-380
Earnings From Continuing Operations	10,393	10,233	7,041	5,961	3,293	115
Minority Interest in Earnings	-4	-8	-6	-6	-5	-3
Net Income	10,389	10,225	7,035	5,955	3,288	112
Net Income to Common	10,389	10,225	7,035	5,955	3,288	112
Net Income Growth	33.67%	45.34%	18.14%	81.11%	2835.71%	-96.50%
Shares Outstanding (Basic)	1,550	1,550	1,550	1,549	1,548	1,418
Shares Outstanding (Diluted)	1,562	1,562	1,563	1,562	1,560	1,427
Shares Change (YoY)	-0.08%	-0.06%	0.06%	0.13%	9.32%	8.68%
EPS (Basic)	6.70	6.60	4.54	3.84	2.12	0.08
EPS (Diluted)	6.64	6.54	4.50	3.81	2.11	0.08
EPS Growth	33.61%	45.33%	18.11%	80.57%	2571.43%	-96.76%
Free Cash Flow	11,293	11,765	9,937	8,984	8,717	4,872
Free Cash Flow Per Share	7.23	7.53	6.36	5.75	5.59	3.41
Dividend Per Share	3.200	3.200	3.100	2.900	2.900	2.870
Dividend Growth	3.23%	3.23%	6.90%	-	1.04%	2.50%
Gross Margin	81.51%	81.71%	82.18%	82.44%	80.52%	67.92%
Operating Margin	24.69%	24.33%	23.91%	21.17%	19.87%	7.74%
Profit Margin	17.19%	17.41%	13.01%	13.00%	7.41%	0.30%
Free Cash Flow Margin	18.68%	20.03%	18.38%	19.61%	19.66%	13.02%
EBITDA	19,994	19,280	17,567	14,275	13,744	6,701
EBITDA Margin	33.08%	32.82%	32.49%	31.16%	30.99%	17.91%
D&A For EBITDA	5,070	4,988	4,638	4,576	4,932	3,804
EBIT	14,924	14,292	12,929	9,699	8,812	2,897
EBIT Margin	24.69%	24.33%	23.91%	21.17%	19.87%	7.74%
Effective Tax Rate	19.52%	17.49%	18.98%	13.60%	-	-
Revenue as Reported	60,439	58,739	54,073	45,811	44,351	37,417

Source: S&P Global Market Intelligence. Standard template. Financial Sources.